Analyzing the T-ALL cohort separately, CDKN2A/2B-deleted patients had non-statistically significant survival differences compared to their T-ALL non-deleted counterparts (EFS 64.3 vs. 69.2, p = 0.947). This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.